Layer-by-Layer Particles Deliver Epigenetic Silencing siRNA to HIV-1 Latent Reservoir Cell Types.


Journal

Molecular pharmaceutics
ISSN: 1543-8392
Titre abrégé: Mol Pharm
Pays: United States
ID NLM: 101197791

Informations de publication

Date de publication:
03 04 2023
Historique:
medline: 4 4 2023
pubmed: 28 2 2023
entrez: 27 2 2023
Statut: ppublish

Résumé

For over two decades, nanomaterials have been employed to facilitate intracellular delivery of small interfering RNA (siRNA), both in vitro and in vivo, to induce post-transcriptional gene silencing (PTGS) via RNA interference. Besides PTGS, siRNAs are also capable of transcriptional gene silencing (TGS) or epigenetic silencing, which targets the gene promoter in the nucleus and prevents transcription via repressive epigenetic modifications. However, silencing efficiency is hampered by poor intracellular and nuclear delivery. Here, polyarginine-terminated multilayered particles are reported as a versatile system for the delivery of TGS-inducing siRNA to potently suppress virus transcription in HIV-infected cells. siRNA is complexed with multilayered particles formed by layer-by-layer assembly of poly(styrenesulfonate) and poly(arginine) and incubated with HIV-infected cell types, including primary cells. Using deconvolution microscopy, uptake of fluorescently labeled siRNA is observed in the nuclei of HIV-1 infected cells. Viral RNA and protein are measured to confirm functional virus silencing from siRNA delivered using particles 16 days post-treatment. This work extends conventional particle-enabled PTGS siRNA delivery to the TGS pathway and paves the way for future studies on particle-delivered siRNA for efficient TGS of various diseases and infections, including HIV.

Identifiants

pubmed: 36848493
doi: 10.1021/acs.molpharmaceut.2c01030
doi:

Substances chimiques

RNA, Small Interfering 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2039-2052

Auteurs

Ewa Czuba-Wojnilowicz (E)

Department of Chemical Engineering, The University of Melbourne, Parkville, Victoria 3010, Australia.

Vera Klemm (V)

Kirby Institute, UNSW Medicine, Sydney, New South Wales 2052, Australia.

Christina Cortez-Jugo (C)

Department of Chemical Engineering, The University of Melbourne, Parkville, Victoria 3010, Australia.

Stuart Turville (S)

Kirby Institute, UNSW Medicine, Sydney, New South Wales 2052, Australia.

Anupriya Aggarwal (A)

Kirby Institute, UNSW Medicine, Sydney, New South Wales 2052, Australia.

Frank Caruso (F)

Department of Chemical Engineering, The University of Melbourne, Parkville, Victoria 3010, Australia.

Anthony D Kelleher (AD)

Kirby Institute, UNSW Medicine, Sydney, New South Wales 2052, Australia.
UNSW RNA Institute, UNSW Sydney, Sydney, New South Wales 2052, Australia.

Chantelle L Ahlenstiel (CL)

Kirby Institute, UNSW Medicine, Sydney, New South Wales 2052, Australia.
UNSW RNA Institute, UNSW Sydney, Sydney, New South Wales 2052, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH